Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study.
Markers of immune stimulation were studied in 76 sequential cerebrospinal fluid (CSF) samples from 19 patients infected with HIV-1 without antiretroviral treatment during observation periods ranging from 22 months to 6 years. Eight of these patients were further followed with 14 CSF samples for 3-24 months of zidovudine treatment. During the course of HIV-1 infection, the mean CSF neopterin and beta 2-microglobulin (beta 2M) concentrations increased from 12.7 to 20.4 nmol/l (p < 0.01) and from 1.93 to 2.17 mg/l (p < 0.05), respectively, while the mean peripheral CD4 + T cell count decreased from 624 to 320 cells x 10(6)/l (p < 0.001). The IgG index, reflecting intrathecal immunoglobulin production, increased from 0.72 to 0.92 (p = 0.08). The number of patients with CSF pleocytosis did not change significantly during follow-up (8/19 at baseline, 7/19 at endpoint). In the 8 patients followed up during antiretroviral treatment, a significant reduction in mean CSF levels of neopterin and beta 2M (-48% and -32%, respectively, p < 0.01) was seen after 3-12 months on zidovudine. We suggest that gradual increase in immune stimulation reflected by the rising CSF concentrations of neopterin and beta 2M indicates that HIV-1 infection in the central nervous system is progressive even in neurologically asymptomatic stages.
Department of Infectious Diseases, University of Göteborg, Sweden.
M
M
Gisslén
F
F
Chiodi
D
D
Fuchs
G
G
Norkrans
B
B
Svennerholm
H
H
Wachter
L
L
Hagberg
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001708:Biopterins / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000276:immunology*; D006679:HIV Seropositivity / Q000134:cerebrospinal fluid / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic; D019798:Neopterin; D015215:Zidovudine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000134:cerebrospinal fluid*
D015415:Biomarkers; D001613:beta 2-Microglobulin; D001708:Biopterins; D015215:Zidovudine; D019798:Neopterin